Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics / Complex genomic and specialised testing for inherited disease and oncology profiling
Complex genomic and specialised testing for inherited disease and oncology profiling
Sequencing-based and array/PCR-plus-molecular specialty products used to diagnose inherited and rare conditions and to profile tumour genomics for targeted therapy selection, including hereditary cancer panels, exome/genome sequencing, tumour tissue and liquid-biopsy profiling, and the associated reagents, kits and interpretation services. Job to be done: produce an analytically and clinically valid, interpretable answer for a complex or treatment-contingent case that routine and rapid panels cannot deliver.
- Level
- Niche
- Segmented by
- Customer type
- Buyers
- Specialised diagnostic providers (reference laboratories, molecular pathology labs) and hospital laboratories operating referral/genomic testing services
- Buying centre
- Molecular pathology and laboratory medicine leadership with clinical genetics and oncology input; purchasing via multi-year reagent/service contracts, with payer and guideline bodies (coverage policies) as an external decision gate.
- Expansion of national or regional hereditary cancer and rare-disease screening programmes
- Targeted-therapy and companion-diagnostic launches requiring tumour profiling
- Guidelines and payer coverage decisions for hereditary and somatic testing
- Turnaround-time and sample-quality requirements for referral testing
- Reimbursement and coding gaps for hereditary and rare-disease testing
- Long turnaround times and sample logistics failures in referral testing
- Interpretation workload and clinical validity/utility evidence burden
- Cost per sample of NGS workflows and consumables versus panel economics
How this was sized
$7.3B ($5.6B–$9.0B) · 2025 · Triangulated
Same USD 22.0B submarket pool (see niche 1 notes). Complex genomic and specialised testing assumed 33% of the submarket = USD 7.26B (range 5.6-9.0B). Forecast: 7,260 x 1.10^5 = USD 11,690M in 2030. 10.0% CAGR is above the 4.78% clinical diagnostics CAGR [1] and the 6.6% diagnostic tests CAGR [3], reflecting molecular mix gain and oncology/hereditary testing adoption; North America alone held 40.0% of clinical diagnostics value in 2025 [1], so this niche is geographically concentrated. Low confidence: the 33% allocation is an assumption; no source in the set sizes molecular diagnostics directly.
- Clinical Diagnostics Market Size, Share, Growth and Forecast, 2025-2035
credenceresearch.com · 2026-10-15 - Global Diagnostic Tests Market Size, Share, Trends and Forecast 2026-2033
pheonixresearch.com · 2026-07-16 - Worldwide Clinical Diagnostics Market 2026 – PW Consulting
pmarketresearch.com · 2026-06-16 - Clinical Diagnostics Market | Clarivant Health
clarivanthealth.com - Laboratory Diagnostics Market 2026 – PW Consulting
pmarketresearch.com · 2026-06-02 - Clinical Diagnostics Market Growth & Forecast 2026-2036
futuremarketinsights.com · 2026-11-02
Alongside it in Molecular and specialised diagnostics
// Sell into Complex genomic and specialised testing for inherited disease and oncology profiling